26th September 2017 Content supplied by: BD Diagnostic Systems
First Automated Phenotypic Test for Carbapenemase Producing Organisms
BD have launchedÂ the first automated phenotypic test* to detect and classify carbapenemase-producing organisms (CPO). Available as part of the BD Phoenixâ„˘ automated microbiology system in Europe, the new BDÂ Phoenixâ„˘ CPO detect test will help hospitals identify and contain infections caused by CPO, while potentially combating an increase in antimicrobial resistance (AMR).
The BD Phoenix CPO detect test, included on BD Phoenixâ„˘ gram-negative panels, identifies CPOs and provides the Ambler classification of the enzyme produced. In contrast to conventional phenotypic methods for CPO detection that can take up to 96 hours, the BD Phoenixâ„˘ CPO detect test can detect CPOs accurately in under 36 hours.
"The BD Phoenix CPO detect test is a completely new type of phenotypic test, and its range of capabilities is unmatched by all currently marketed tests," said Kenneth S. Thomson, PhD, FIDSA, FAAM, FASM clinical professor of Pathology and Laboratory Medicine, University of Louisville School of Medicine. "It represents a significant advance in meeting an important clinical need."
Fully integrated within BD Phoenix panels, the new BD Phoenix CPO detect test enables laboratories to offer a more comprehensive antimicrobial susceptibility test profile while improving laboratory process efficiency. The test is available in two configurations, offering flexibility to customers; a combo panel that detects the presence of CPOs, and the BD Phoenixâ„˘ emerge panel that detects the presence of CPOs and if positive, provides the Ambler classification of the carbapenemase.
"The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management," said Steve Conly, vice president of Microbiology for BD. "Along with the BD Phoenixâ„˘ M50, this first-to-market phenotypic automated test to detect CPOs, expands BD's portfolio of solutions for identification and antimicrobial susceptibility testing (ID/AST) and is another example of the company's commitment to combating AMR."
Visit bd.com/ds for more information
*Currently available for sale in Europe. Product not available for sale in the US.
Date Published: 26th September 2017
Source article link: http://investors.bd.com/phoenix.zhtml?c=64106&p=irol-newsArticle&ID=2302778
Bruker Acquires MERLIN Adding Speciality
Arup Offers Explifyâ„˘ Respiratory a